Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516176 | 1.00 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4OPRM1OPRD1 | |
| SCHEMBL4727093 | 0.87 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4727094 | 0.87 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4727088 | 0.87 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3745512 | 0.86 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3515881 | 0.86 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3515884 | 0.86 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3514322 | 0.85 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3517323 | 0.85 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3514320 | 0.85 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | SLC6A3 3560/4885SLC6A2 3752/4885SLC6A4 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.